$37.5M Offering Priced With Warrants Covering 93.6M Shares — Massive Dilution for InspireMD
NSPR sits 48% above its 52-week low of $0.425 on elevated volume (5.3× avg).
Summary
InspireMD priced the offering it launched November 12 at $37.5 million, selling 7,342,308 common shares plus pre-funded warrants for 50,350,000 shares and common warrants for 43,269,231 shares. The warrant coverage is enormous relative to the company's roughly $36 million market cap, so existing holders face severe dilution. The raise follows a Q3 in which U.S. sales collapsed to $32K from $497K after the recall and cash fell to $19.2M from $54.2M, and it comes one day after the FDA approved the CGuard Prime PMA supplement. Lake Street is sole bookrunner, with closing expected on or about November 16, 2026, and proceeds earmarked for R&D, sales and marketing, and working capital. The pricing terms — including the per-unit price — were not disclosed in this release, so the discount to the $0.63 last price is unknown.
At the time of this announcement, NSPR was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.